Anna Juhász

Anna Juhász

Auto-generated profile, based on publicly available information

Anna Juhász

Department of Psychiatry, Faculty of Medicine, University of Szeged, 6725 Szeged, Hungary

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Psychiatry Research
Verified
Journal Article
Closed access
ÁFÁgnes Fehér
Ágnes Fehér
AJAnna Juhász
Anna Juhász
MPMagdolna Pákáski
Magdolna Pákáski
KJKálmán János
Kálmán János
ZJZoltán Janka
Zoltán Janka

18 February 2019 in Molecules
Verified
Journal Article
Open access
PDF file
Renáta SzabóRenáta Szabó
Renáta Szabó
RMRudolf Ménesi
Rudolf Ménesi
AMAndor H. Molnár
Andor H. Molnár
ZSZita Szalai
Zita Szalai
LDLejla Daruka
Lejla Daruka
APAnikó Pósa
Anikó Pósa
Background: The hypothalamic–pituitary axis by secreting neuropeptides plays a key role in metabolic homeostasis. In light of the metabolic regulation, oxytocin is a potential neuropeptide for therapies against obesity and related disorders. The aim of our study is to measure ghrelin-induced oxytocin secretion in rats and to detect the changes after administration of ghrelin antagonist. Methods: Ghrelin was administrated centrally (intracerebroventricular, i.c.v., 1.0, 10.0, and 100.0 pmol) or systemically (intravenous, i.v., 1.0, and 10.0 nmol). [d-Lys3]-GHRP-6 ghrelin antagonist was injected 15 min before ghrelin injection in a dose of 10.0 pmol i.c.v. and 10.0 nmol i.v. Results: Either i.c.v. or i.v. administration of ghrelin dose-dependently increased the plasma oxytocin concentration. Following pretreatment with the ghrelin antagonist [d-Lys3]-GHRP-6, the high plasma oxytocin level induced by ghrelin was significantly reduced. Conclusion: The results indicate that the release of oxytocin is influenced directly by the ghrelin system. Examination of the mechanism of ghrelin-induced oxytocin secretion is a new horizon for potential therapeutic options.

1 October 2011 in Psychiatric Genetics
Verified
Journal Article
Closed access
ÁFÁgnes Fehér
Ágnes Fehér
AJAnna Juhász
Anna Juhász
ÁRÁgnes Rimanóczy
Ágnes Rimanóczy
MPMagdolna Pákáski
Magdolna Pákáski
JKJános Kálmán
János Kálmán
ZJZoltán Janka
Zoltán Janka
Calcium homeostasis modulator 1 (CALHM1), a promising candidate gene for Alzheimer's disease risk, has been recently identified. We tested the hypothesis that the T-allelic variant of the CALHM1 rs2986017 polymorphism confers susceptibility to Alzheimer's disease in a Hungarian case–control sample that was also genotyped for apolipoprotein E. This study included 238 probable patients with Alzheimer's disease who met the diagnostic criteria for National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association and 202 elderly healthy control participants. We failed to detect an association between the CALHM1 polymorphism and the risk for Alzheimer's disease (P=0.153 for genotypes and P=0.090 for alleles), nor did we find an effect on age at onset. However, a potential weak correlation between the presence of the T allele (CT and TT genotypestogether) and Alzheimer's disease was observed (P=0.056).

1 December 2003
Verified
Journal Article
Closed access
JKJános Kálmán
János Kálmán
AJAnna Juhász
Anna Juhász
ARAgnes Rimanóczy
Agnes Rimanóczy
APAndrás Palotás
András Palotás
MPMiklós Palotás
Miklós Palotás
ZJZoltán Janka
Zoltán Janka
An association study was performed between apolipoprotein E (apoE) polymorphism and the common structural polymorphism Glu/Asp at codon 298 of the nitric oxide synthase (NOS3) gene in late-onset sporadic Alzheimer's dementia probands (LOAD), diffuse Lewy body dementia cases (DLBD) and controls in a Hungarian sample. The frequency of individuals who carried the apoE epsilon4 allele was significantly more common in both dementia groups (LOAD, 20%; DLBD, 27%; control, 8%; control versus DLBD, chi2=13.264, degrees of freedom=2, P<0.001; control versus LOAD, chi2=6.628, degrees of freedom=2, P<0.036). However, there were no significant differences in the NOS3 genotype and allele distributions between the LOAD, DLBD and control groups. The apoE status has been found to be independent from the NOS3 codon 298 polymorphism in the examined cohort. Despite the facts that NOS3 is associated with neuritic sprouting, and aberrant neuronal and glial expression of the same molecule has been found in neurodegenerative diseases, it is unlikely that the polymorphism Glu/Asp of the NOS3 gene is involved in the development of LOAD and DLBD.

1 March 2012
Verified
Journal Article
Closed access
JKJanos Kovacs
Janos Kovacs
MPMagdolna Pákáski
Magdolna Pákáski
AJAnna Juhasz
Anna Juhasz
AFAgnes Feher
Agnes Feher
GDGergely Drotos
Gergely Drotos
JKJanos Kalman
Janos Kalman

30 April 2011 in Psychiatry Research
Verified
Journal Article
Closed access
PÁPéter Z. Álmos
Péter Z. Álmos
Szatmar HorvathSzatmar Horvath
Szatmar Horvath
ÁCÁgnes Czibula
Ágnes Czibula
IRIstván Raskó
István Raskó
NDNóra Domján
Nóra Domján
JKJános Kálmán
János Kálmán